when was bpc 157 banned FDA's Overreach on Compounded Peptides The Hidden Risks of BPC‑157:

Thereby, as a cause-consequence relation appears the counteracted muscle atrophy, no more inflammatory infiltrate in the BPC 157 group, well-oriented recovered tissue of myotendinous junction in BPC 157 treated rats at the 28 days and 42 days

More studies are needed before such strong statements can be made

Cerebellum and nonmotor function

$33 for a 30-day supply No gimmicks, no fads, just science *In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)